Beyond the Scale: Orderly Wellness and Veo Health Team Up to Give GLP-1 Patients the Full Picture

New partnership pairs OrderlyMeds' GLP-1 therapies with Veo Health's biomarker testing so customers can see — and act on — what's really changing inside their bodies.

ATLANTA, Sept. 9, 2026 /PRNewswire/ -- OrderlyMeds and Veo Health today announced a strategic partnership that looks past the scale — pairing OrderlyMeds' GLP-1, peptide and longevity therapies with Veo Health's advanced biomarker testing and body composition analysis so customers can monitor health improvements and assess specific changes to their health during a weight-loss journey.

Through the partnership, OrderlyMeds customers gain access to two new Veo Health membership tiers built for the GLP-1 journey: Veo Core (60+ biomarkers and AI-powered insights) and Veo Pro (80+ biomarkers, physician and health-advisor consultations, and a personalized health action plan). Veo Health members, in turn, get discounted access to OrderlyMeds' therapeutic platform and clinical network.

"At Orderly, we believe the best treatment is prevention. By pairing our accessible therapeutic programs with Veo's health monitoring and coaching platform, we're giving people a complete toolkit — not just to manage their health, but to get ahead of it," said Chris Spears, CEO, Orderly Wellness Corporation. "Partnering with Veo gives our customers a much broader view of their health — and the tools and expertise to act on what they learn."

The partnership connects the full arc of health optimization — measure, understand, treat, monitor and optimize — pairing Veo Health's national lab and mobile phlebotomy network, DEXA scans, wearable-device integrations and concierge clinical experts with OrderlyMeds' prescribing, coaching and clinical infrastructure.

"The goal isn't simply to help someone lose weight," said David Harvey, CEO, Veo Health. "It's to use that journey as a catalyst for better health and longevity."

About Orderly Wellness

As a part of Orderly Wellness, OrderlyMeds is a telemedicine platform connecting customers with licensed physicians across all 50 states to access prescription GLP-1 medications, including compounded and brand-name treatments. More than 125,000 customers have used OrderlyMeds to improve their health, collectively shedding over 1 million pounds; individual results may vary. Learn more at www.orderlymeds.com.

Compounded GLP-1 medications are not FDA-approved and are not generic versions of, or substitutes for, FDA-approved drugs. They are prescribed only based on an individualized medical determination by a licensed healthcare provider.

About Veo Health

Based in Atlanta, Veo Health is a physician-led preventive health platform that helps individuals identify health risks earlier and act on them, through advanced biomarker screenings and imaging along with guidance from physicians, functional nutritionists and health advisors. Learn more at www.veo.health.

SOURCE Veo Health